Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 16 de 16
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eur J Obstet Gynecol Reprod Biol ; 39(1): 71-5, 1991 Mar 21.
Artigo em Inglês | MEDLINE | ID: mdl-2029960

RESUMO

Two patients with primary squamous cell carcinoma of the uterus are described. In both patients, the disease was at an advanced stage when the diagnosis was made. Although endometrial malignancies with squamous elements account for 10-30% of endometrial carcinomas, primary squamous cell carcinoma of the uterus is extremely rare. Up to now fewer than 30 cases have been reported. The pathogenesis, morphogenesis and aetiology of squamous epithelium in the corpus uteri is discussed. Finally, some clinical aspects of the primary squamous cell carcinoma of the corpus uteri are reviewed.


Assuntos
Carcinoma de Células Escamosas/patologia , Neoplasias Uterinas/patologia , Idoso , Neoplasias Encefálicas/secundário , Carcinoma de Células Escamosas/diagnóstico , Carcinoma de Células Escamosas/etiologia , Feminino , Humanos , Neoplasias Uterinas/diagnóstico , Neoplasias Uterinas/etiologia , Útero/patologia
2.
Geburtshilfe Frauenheilkd ; 44(2): 100-3, 1984 Feb.
Artigo em Alemão | MEDLINE | ID: mdl-6564042

RESUMO

Abdominovaginal sling procedures are one of the operative methods for treating urinary stress incontinence in women. They are used especially in incontinence associated with severe pelvic floor weakness. By suspending the vesicourethral junction to the anterior abdominal wall by help of a dural or fascial sling, the bladder neck and proximal urethra are restored to their original anatomical position. Changes in intraabdominal pressure are transmitted equally to both bladder and urethra. One of the difficulties during the course of the operation is to maintain proper tension to the sling while suturing it to the rectus sheath. If the sling is placed to loosely, therapeutic failure may result; on the other hand, overtightening of the sling can lead to delayed voiding and retention of urine. With this problem in mind, urethral pressure recordings were performed during the course of 14 abdominovaginal sling operations. Significant changes concerning the functional urethral profile length, the maximum urethral pressure, and especially the shape of the urethral closure pressure profile could be demonstrated following the main operative steps.


Assuntos
Uretra/fisiopatologia , Incontinência Urinária por Estresse/cirurgia , Feminino , Humanos , Masculino , Manometria , Recidiva , Bexiga Urinária/fisiopatologia , Incontinência Urinária por Estresse/fisiopatologia , Micção
3.
Z Geburtshilfe Perinatol ; 185(2): 89-93, 1981 Apr.
Artigo em Alemão | MEDLINE | ID: mdl-7196123

RESUMO

A group of 29 patients who had premature labour contractions were chosen to take part in this study. All were cardiovascularly healthy. Their performance during a step climbing exercise was examined in relationship to a Fenoterol-tocolysis (30-60 mg/day) and to the amount of exercise. The fetal heart rate showed no pathological changes following the exercise, as compared to the preexercise values. An external tocometry showed the uterine activity also to be uninfluenced.


Assuntos
Etanolaminas/uso terapêutico , Fenoterol/uso terapêutico , Trabalho de Parto Prematuro/prevenção & controle , Esforço Físico , Determinação da Pressão Arterial , Eletrocardiografia , Feminino , Coração Fetal , Frequência Cardíaca/efeitos dos fármacos , Humanos , Gravidez , Contração Uterina/efeitos dos fármacos
4.
Arch Gynecol ; 230(3): 231-7, 1981.
Artigo em Inglês | MEDLINE | ID: mdl-7247466

RESUMO

None of the betamimetics have a exclusively tocolytic effect. By stimulating the cardiovascular beta-receptor, they also cause a substantial increase in the heart rate and a decrease in blood pressure. We administered 4--5 micrograms/min of Fenoterol to 13 patients during the first stage of labour. This led to complete inhibition of labour. To reduce cardiac side effects, a primarily cardiac beta-blocker (5 mg Atenolol or 20 mg Metoprolol) was also given. The maternal and fetal heart rates were measured by ECG and by fetal scalp-electrode, respectively. The fetal heart rate remained largely unchanged, both during the Fenoterol infusion as well as during the additional administration of the beta-blocker. The maternal heart rate, which increased under the influence of the Fenoterol, fell (p less than or equal to 0.01) but did not return to normal. In all cases the beta-blockade led to a brief increase in uterine activity.


Assuntos
Atenolol/uso terapêutico , Etanolaminas/uso terapêutico , Fenoterol/uso terapêutico , Metoprolol/uso terapêutico , Complicações do Trabalho de Parto/tratamento farmacológico , Propanolaminas/uso terapêutico , Pressão Sanguínea/efeitos dos fármacos , Feminino , Fenoterol/efeitos adversos , Frequência Cardíaca/efeitos dos fármacos , Humanos , Gravidez , Taquicardia/induzido quimicamente , Taquicardia/tratamento farmacológico
5.
Dtsch Med Wochenschr ; 105(38): 1320-4, 1980 Sep 19.
Artigo em Alemão | MEDLINE | ID: mdl-7460777

RESUMO

Tocolytic treatment with fenoterol and additional administration of betamethasone and acetyl salicylic acid to a 19-year-old girl caused irreversible and finally fatal pulmonary changes. The clinical course in this and that of other published cases indicates a causal relationship between the tocolytic treatment and the onset of pulmonary oedema. The pulmonary arterial pressures in this patient, the poor therapeutic response and the shock-lung picture without corresponding myocardial changes suggest a non-cardiogenic cause of pulmonary oedema. Any of the three drugs administered could have been responsible.


Assuntos
Etanolaminas/efeitos adversos , Fenoterol/efeitos adversos , Edema Pulmonar/induzido quimicamente , Adulto , Aspirina/efeitos adversos , Autopsia , Betametasona/efeitos adversos , Feminino , Humanos , Trabalho de Parto Prematuro/prevenção & controle , Gravidez , Edema Pulmonar/patologia , Síndrome do Desconforto Respiratório/induzido quimicamente , Síndrome do Desconforto Respiratório/patologia
6.
Z Geburtshilfe Perinatol ; 183(5): 339-42, 1979 Oct.
Artigo em Alemão | MEDLINE | ID: mdl-543183

RESUMO

In the investigation of possible myocardial damage, the assay of the heart specific isoenzyme kreatinkinase MB has established itself as a highly sensitive proof of a heart necrosis. In patients who underwent stationary treatment for premature contractions, the CK-activity was measured in the initial phase of tocolysis and additionally right before the therapy was ended. There was no laboratory indication of any heart damage due to tocolytic treatment.


Assuntos
Creatina Quinase/metabolismo , Etanolaminas/uso terapêutico , Fenoterol/uso terapêutico , Trabalho de Parto Prematuro/tratamento farmacológico , Feminino , Coração/efeitos dos fármacos , Humanos , Isoenzimas , Potássio/sangue , Gravidez
10.
Geburtshilfe Frauenheilkd ; 38(10): 831-9, 1978 Oct.
Artigo em Alemão | MEDLINE | ID: mdl-212344

RESUMO

20 girls, their age being between 8 to 13 years, with an actual height above the 97th percentile received 10,0 mg conjugated estrogens per day cyclicly or 0,3 mg ethinylestradiol continuously over a period of 0,3 to 3,8 years, in order to inhibit excessive growth. The duration of therapy ranged from 0,6 to 3,8 years regularly. Before and during treatment the patients were examined, and each time the expected final height was calculated based on the actual height and the bone age. The stage of puberty was defined according to Blizzard, and the determination of the bone age was performed as described by Tanner and Whitehouse. The extragenital side effects were also recorded. The effectiveness of the estrogen treatment, i. e. the reduction of the expected final height, depends on the chronological age, the skeletal age and the stage of puberty before therapy. It ranged between 0,5 and 5,1 cm. The earlier treatment was started the better were the results. The effectiveness was more obvious in cases with continuous estrogen treatment. No serious side effects could be observed.


Assuntos
Estrogênios Conjugados (USP)/uso terapêutico , Etinilestradiol/uso terapêutico , Gigantismo/tratamento farmacológico , Adolescente , Fatores Etários , Estatura , Desenvolvimento Ósseo , Criança , Estrogênios Conjugados (USP)/efeitos adversos , Etinilestradiol/efeitos adversos , Feminino , Crescimento/efeitos dos fármacos , Humanos , Noretindrona/uso terapêutico , Puberdade
13.
Geburtshilfe Frauenheilkd ; 37(4): 297-303, 1977 Apr.
Artigo em Alemão | MEDLINE | ID: mdl-140094

RESUMO

The paper refers to 167 patients who were treated with 2 mg Cyproteronacetate and 50 mug Ethinyloestradiol because of acne, seborrhoea, hirsutism and androgenetic alopecia. The application was daily from the 5th to the 25th day of cycle over a period of 12 months. The success of treatment depended on the severity of virilisation: in cases of light acne only 77% of the patients showed improvement, while in cases of severe acne 91,4% showed improvement or healing of acne. The corresponding figures for seborrhoea were 55,7% and 89,4% respectively, and for hirsutism 37,4% and 60,9% respectively. Furthermore the success of treatment of the different virilising symptoms depended on the duration of therapy: while acne was already cured significantly after 6 months of treatment, seborrhoea and hirsutism show continuous improvement up to the 10th month thetherapy. Concerning side effects during therapy spottings and brake through bleedings were registered in 17,1 and 6% of cycles respectively. 16,2% of the patients noted breast tensions. Finally 68,7% of the patients suffered from nervousness, a very subjective symptom, which might be explained by the psychic lability accompanying virilising symptoms. The drop out rate was 7,8%, being not higher than with other oral contraceptives.


Assuntos
Ciproterona/uso terapêutico , Etinilestradiol/uso terapêutico , Virilismo/tratamento farmacológico , Acne Vulgar/tratamento farmacológico , Alopecia/tratamento farmacológico , Ciproterona/administração & dosagem , Ciproterona/efeitos adversos , Dermatite Seborreica/tratamento farmacológico , Etinilestradiol/administração & dosagem , Etinilestradiol/efeitos adversos , Feminino , Hirsutismo/tratamento farmacológico , Humanos , Distúrbios Menstruais/tratamento farmacológico , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...